Gemini Therapeutics, Inc. (GMTX)
Market Closed
13 Jun, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
53. 71
+1
+1.9%
$
25.49M Market Cap
- P/E Ratio
0% Div Yield
705,221 Volume
- Eps
$ 52.71
Previous Close Day Range
51.52 54.13
Year Range
30.82 68.73
Summary
GMTX closed Friday higher at $53.71, an increase of 1.9% from Thursday's close, completing a monthly increase of 14.11% or $6.64. Over the past 12 months, GMTX stock lost -15.89%.
GMTX is not paying dividends to its shareholders.
Gemini Therapeutics, Inc. has completed 1 stock splits, with the recent split occurring on Dec 30, 2022.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).
Want to track GMTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
GMTX Chart
Gemini Therapeutics, Inc. Dividends
GMTX is not paying dividends to its shareholders.
Gemini Therapeutics, Inc. Earnings
GMTX have yet to publish their earning reports.
GMTX is not paying dividends to its shareholders.
GMTX have yet to publish their earning reports.
Gemini Therapeutics, Inc. (GMTX) FAQ
What is the stock price today?
The current price is $53.71.
On which exchange is it traded?
Gemini Therapeutics, Inc. is listed on NASDAQ (NMS).
What is its stock symbol?
The ticker symbol is GMTX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 25.49M.
Has Gemini Therapeutics, Inc. ever had a stock split?
Gemini Therapeutics, Inc. had 1 splits and the recent split was on Dec 30, 2022.
Gemini Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | NASDAQ (NMS) Exchange | 36870G105 Cusip |
| US Country | 24 Employees | - Last Dividend | 30 Dec 2022 Last Split | - IPO Date |
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Contact Information
Address: 300 One Kendall Square
Phone: 212 600 1902
Website: https://www.geminitherapeutics.com
2025 © Marketlog. All Rights Reserved.
